Low generation polyamidoamine dendrimers (PAMAM) and biotin-PAMAM conjugate – the detailed structural studies by 1H and 13C nuclear magnetic resonance spectroscopy
DOI:
https://doi.org/10.15584/ejcem.2020.4.4Keywords:
biotin conjugate, nuclear magnetic resonance, polyamidoamine dendrimerAbstract
Introduction. The concept of targeted drug delivery is nowadays based on nanoparticle transporters. Such drug delivery systems for cancer cells should follow the requirements like: efficient drug release, selective binding and internalization to cancer cells. The anticancer drug selectivity can be achieved by attachment of cancer cell-recognizing molecules, like biotin. Among nanosized carriers the PAMAM dendrimers are tested intensely, especially they can be modified by covalent attachment of prodrug molecules and biotin as targeting molecule.
Aim. We aimed at construction and characterization of a conjugate formed between PAMAM and biotin (Biot). The nuclear magnetic resonances is powerful tool to determine both the structure and stoichiometry of the conjugate.
Material and methods. PAMAM G0 has been synthesized and functionalized with biotin by reaction with N-hydroxysuccinimide ester of biotin to obtain G0 double-substituted with biotin. All the compound were thoroughly characterized by the NMR spectroscopy.
Results. The conjugate of PAMAM G0 dendrimer with two amide-bonded biotin molecules was obtained and fully characterized by NMR spectroscopy.
Conclusion. N-hydroxysuccinimide ester of biotin spontaneously reacts with PAMAM G0 to obtain the conjugate of 2:1 biotin:G0 stoichiometry. The latter was designed as a targeting molecule in formation of megameric multidrug delivery system.
Downloads
References
Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Publisher September 12, 2018. Accessed November 10, 2020.
Economic Impact of Cancer. https://www.cancer.org/cancer/cancer-basics/economic-impact-of-cancer.html. Publisher January 3, 2018. Accessed November 15, 2020.
Moorthi C, Manavalan R, Kathiresan K. Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations. J Pharm Pharmaceut Sci. 2011; 14(1): 67-77.
Kou L, Yao Q, Zhang H, Chu M, Bhutia YD, Chen R, Ganapathy V. Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery. Cancers. 2020; 12: 2837.
Sadekar S, Ghandehari H. Transepithelial Transport and Toxicity of PAMAM Dendrimers: Implications for Oral Drug Delivery. Adv Drug Deliv Rev. 2012; 64(6): 571-588.
Czerniecka-Kubicka A, Tutka P, Pyda M, et al. Stepwise glucoheptoamidation of poly(amidoamine) dendrimer G3 to tune physicochemical properties of the potential drug carrier; in vitro tests for cytisine conjugates. Pharmaceutics. 2020; 12: 473.
Vadlapudi AD, Vadlapatla RK, Pal D, Mitra AK. Biotin uptake by T47D breast cancer cells: Functional and molecular evidence of sodium-dependent multivitamin transporter (SMVT). Int J Pharm. 2013; 441: 535-543.
Patel M, Vadlapatla RK, Shah S, Mitra AK. Molecular expression and functional activity of sodium dependent multivitamin transporter in human prostate cancer cells. Int J Pharm. 2012; 436: 324-331.
Russell-Jones G, McTavish K, McEwan J. Rice J, Nowotnik D. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem. 2004; 98: 1625-1633.
Hanurry EY, Mekonnen TW, Andrgie AT, et al. Biotin-Decorated PAMAM G4.5 Dendrimer Nanoparticles to Enhance the Delivery, Anti Proliferative, and Apoptotic Effects of Chemotherapeutic Drug in Cancer Cells. Pharmaceutics. 2020; 12: 443.
Uram Ł, Misiorek M, Pichla M, et al. The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro. Molecules. 2019; 24: 3801.
Yang W, Cheng Y, Xu T, Wang X, Wen L. Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem. 2009; 44: 862-868.
Yellepeddi VK, Kumar A, Palakurthi S. Biotinylated Poly(amido)amine (PAMAM) Dendrimers as Carriers for Drug Delivery to Ovarian Cancer Cells In Vitro. Anticancer Res. 2009; 29: 2933-2944.
Tomalia D, Baker H, Dewald J, et al. A new Class of Polymers: Starburst-Dendritic Macromolecules. Polym J .1985; 17: 117-132.
Zaręba M, Sareło P, Kopaczyńska M, et al. Mixed-Generation PAMA M G3-G0 Megamer as a Drug Delivery System for Nimesulide: Antitumor Activity of the Conjugates Against Human Squamous Carcinoma and Glioblastoma Cells. Int J Mol Sci. 2019; 20: 4998.
Uram Ł, Markowicz J, Misiorek M, et al. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent. Eur J Pharm Sci. 2020; 152: 105439.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
